

Publications 2022-2023:

1. Xue-Bin Ran, **Ling-Wen Ding (Co-Corresponding author)**, Qiao-Yang Sun, Henry Yang, Jonathan W Said, Zhen-Tang Lao, Vikas Madan, Pushkar Dakle, Jin-Fen Xiao, Xin-Yi Loh, Ying Li, Liang Xu, Xiao-Qiang Xiang, Ling-Zhi Wang, Boon Cher Goh, De-Chen Lin, Wee Joo Chng, Soo Yong Tan, Sudhakar Jha and H. Phillip Koeffler. Targeting RNA exonuclease XRN1 potentiates efficacy of cancer immunotherapy. **Cancer Research**, 2023. **IF=13.312**
2. Win Lwin Thuya, Li Ren Kong, Nicholas L. Syn, **Ding Ling Wen (Co-First author)**, Esther Sok Hwee Cheow, Regina Tong Xin Wong, Tingting Wang, Robby Miguel Wen-Jing Goh, Song Hongyan, Minh TN Le, Hu Jian Cheng, Wei Peng Yong, Soo Chin Lee, Andrea Li-Ann Wong, Gautam Sethi, Huynh The Hung, Paul Chi-Lui Ho, Jean-Paul Thiery, Siu Kwan Sze, Tiannan Guo, Ross A. Soo, Henry Yang, Yaw Chyn Lim, Lingzhi Wang, Boon Cher Goh. FAM3C in circulating tumor-derived extracellular vesicles promotes non-small cell lung cancer growth in secondary sites. **Theranostics**, 2023. **IF=11.6**
3. Pei Huang, Lingsheng Jiang, Hui Pan, **Lingwen Ding**, Bo Zhou, Mengyao Zhao, Jianhua Zou, Benhao Li, Meiwei Qi, Hongzhang Deng, Yongfeng Zhou, Xiaoyuan Chen. Integrated Polymeric mRNA Vaccine without Inflammation Side-Effects for Cellular Immunity Mediated Cancer Therapy. **Advanced Materials**. 2022 Nov 3;e2207471. **IF=32.09**
4. Jin-Fen Xiao, Ley-Fang Kua, **Ling-Wen Ding**, Qiao-Yang Sun, Khine Nyein Myint, Xiu-Rong Chia, Nachiyappan Venkatachalam, Xinyi Loh, Jason E Duex, Vanessa Neang, Siqin Zhou, Ying Li, Henry Yang, H Phillip Koeffler, Dan Theodorescu. KDM6A depletion in breast epithelial cells leads to reduced sensitivity to anticancer agents and increased TGF- β activity. **Molecular Cancer Research**. 2022;20(4):637-649. **IF=6.333**

Grant 2022-2023:

- **Principal Investigator**, Targeting RNA exonuclease XRN1 to potentiate immune checkpoint blockade therapy. NMRC Open Fund - Individual Research Grant (OF-IRG), 2021 Nov grant call (OFIRG21nov-0039, 1.2 million SGD, Oct 2022-Oct 2027).
- **Principal Investigator**, RNA vaccine against public tumor antigens. NUS Medical School Startup funding, 2023, 0.5 million SGD, 36 Months.
- **Team Principal Investigator**, Development of Individualized Cancer Vaccines. The National Research Foundation (NRF) 28th Competitive Research Programme (CRP) Call (7.845 million SGD, Lead PI: Prof. Xiaoyuan Chen). 5 Years